{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is 89bio, Inc. technically bullish or bearish?
As of October 10, 2025, 89bio, Inc. shows a mildly bullish trend with mixed indicators, having outperformed the S&P 500 significantly over the past month and year, but underperformed over the 5- and 10-year periods.
Is 89bio, Inc. technically bullish or bearish?
As of October 10, 2025, 89bio, Inc. shows a mildly bullish trend with mixed technical indicators, having outperformed the S&P 500 significantly over the past month and year, but underperformed over the 5- and 10-year periods.
Is 89bio, Inc. technically bullish or bearish?
As of October 3, 2025, 89bio, Inc. shows a bullish trend supported by positive MACD and Bollinger Bands signals, despite bearish RSI readings indicating potential short-term caution, while significantly outperforming the S&P 500 over the past month and year.
Is 89bio, Inc. technically bullish or bearish?
As of October 3, 2025, 89bio, Inc. shows a bullish trend supported by strong performance metrics, despite some mixed signals in shorter-term indicators like RSI and KST.
Is 89bio, Inc. technically bullish or bearish?
As of October 3, 2025, 89bio, Inc. shows a bullish trend supported by positive technical indicators, despite bearish RSI readings suggesting caution, and has significantly outperformed the S&P 500 over the past month and year.
Is 89bio, Inc. technically bullish or bearish?
As of September 11, 2025, 89bio, Inc. shows a mildly bullish trend with strong performance, having a year-to-date return of 91.30% compared to the S&P 500's 12.22%, despite some bearish signals in momentum indicators.
89bio, Inc. Hits New 52-Week High of $15.06, Up 76.62%
89bio, Inc. has achieved a new 52-week high of USD 15.06, reflecting a significant increase in its stock performance over the past year. With a market capitalization of USD 1,271 million, the company has shown a strong upward trend, despite being a loss-making entity.
Is 89bio, Inc. technically bullish or bearish?
As of June 3, 2025, the technical trend is mildly bullish, supported by positive indicators such as bullish MACD, moving averages, and Bollinger Bands across multiple time frames.
Who are in the management team of 89bio, Inc.?
As of March 2022, the management team of 89bio, Inc. includes Dr. Steven Altschuler (Independent Chairman), Mr. Rohan Palekar (CEO and Director), and five Independent Directors: Dr. Derek DiRocco, Dr. Gregory Grunberg, Dr. Michael Hayden, and Ms. Anat Naschitz.
What does 89bio, Inc. do?
89bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and cardio-metabolic diseases, with a market cap of approximately $1.45 billion and a recent net profit of -$71 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap entity.
How big is 89bio, Inc.?
As of Jun 18, 89bio, Inc. has a market capitalization of $1.45 billion, with net sales of $0.00 million and a net profit of -$386.67 million over the last four quarters. The company reported shareholder's funds of $400.79 million and total assets of $478.69 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
